Effect of rifampicin and clarithromycin on the CYP3A activity in patients with Mycobacterium avium complex | Zendy

Norimichi Akiyama | Zendy; Naoki Inui | Zendy; Kazutaka Mori | Zendy; Yutaro Nakamura | Zendy; Hiroshi Hayakawa | Zendy; Shimako Tanaka | Zendy; Shinya Uchida | Zendy; Noriyuki Namiki | Zendy; Hiroshi Watanabe | Zendy; Takafumi Suda | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Effect of rifampicin and clarithromycin on the CYP3A activity in patients with Mycobacterium avium complex

Author(s) -

Norimichi Akiyama,

Naoki Inui,

Kazutaka Mori,

Yutaro Nakamura,

Hiroshi Hayakawa,

Shimako Tanaka,

Shinya Uchida,

Noriyuki Namiki,

Hiroshi Watanabe,

Takafumi Suda

Publication year - 2019

Publication title -

journal of thoracic disease

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.682

H-Index - 60

eISSN - 2077-6624

pISSN - 2072-1439

DOI - 10.21037/jtd.2019.09.06

Subject(s) - clarithromycin , cyp3a , rifampicin , medicine , nontuberculous mycobacteria , mycobacterium avium intracellulare infection , mycobacterium , pharmacology , pharmacokinetics , microbiology and biotechnology , cyp3a4 , antibiotics , cytochrome p450 , biology , tuberculosis , pathology , metabolism

The prevalence of pulmonary infections caused by nontuberculous mycobacteria (NTM) is increasing worldwide. Furthermore, the treatment of infections caused by the Mycobacterium avium-intracellulare complex (MAC) remains challenging. The cytochrome P450 (CYP) enzyme inducer, rifampicin, and the CYP inhibitor, clarithromycin, have clinical activity against MAC and key drugs in the treatment of MAC infection. The interaction of rifampicin and clarithromycin may influence the therapeutic process.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research